Tesis

Kualitas Hidup Pasien HIV Pasca Menjalani Program Transisi Terapi dari Antiretroviral Zidovudine/ Lamivudine/ Nevirapine ke Tenofovir/ Lamivudine/ Dolutegravir = Quality of life After Transitioning from Antiretroviral Therapy Zidovudine/ Lamivudine/ Nevirapine to Tenofovir/ Lamivudine/ Dolutegravir in Stable PLWH.

Latar Bclakang: Indonesia menjalani program transisi pengobatan ARV pada ODHIV yang sudah stabil dengan terapi ARV berbasis nevirapine ke dolutegravir sejak 2023. Tujuan: Mengetahui perubahan kualitas hidup setelah 6 bulan menjalani transisi dari ARV zidovudine/ lamivudine/ nevirapine ke tenofovir/ lamivudine/ dolutegravir ( I LD). Metode: Penelitian ini menggunakan desain kohort retrospektif terhadap 145 subjek yang menjalani program transisi. Kualitas hidup dinilai dengan kuisoner EQ-5D-3L versi bahasa Indonesia Hasil: Dari 145 subjek penelitian, 83 (57,2%) subjek pria, median umur 43 (40 - 46,5) tahun dan 144 (99,3%) subjek dengan virus tidak terdeteksi Median skor VAS EQ- 5D-3L 90 (RIK 80- 99) vs 90 (RIK 85 -100) (p < 0,001) dan median skor utilitas EQ-5D-3L 1 (RIK 1 - 1) vs 1 (RIK 1- 1) (p= 0,021). Simpulan: Ada perbaikan kualitas hidup berdasarkan skor VAS pasca menjalani program transisi antiretroviral meskipun dijumpai perburukan nyeri berdasarkan skor utilitas
Kata kunci: Nevirapine, transisi, dolutegravir, kualitas hidup


Background: Indonesia has been undergoing a transition program with stable PLWH from nevirapine to dolutegravir-based antiretroviral therapy since 2023. Objective: To determine the changes in quality' of life after six months of transition from zidovudine/ lamivudine/ nevirapine to tenofovir/ lamivudine/ dolutegravir (TLD) Methods: This study used a retrospective cohort design of 145 subjects undergoing the transition program. Quality' of life was assessed with the Indonesian version of the EQ-5D-3L questionnaire before and after six months of transition. Results: Of the 145 study subjects, 83 (57.2%) subjects wrere male, median age 43 (40 - 46.5) years, and 144 (99 3%) subjects with undetectable virus. Median EQ-5D-3L VAS score 90 (ICR 80 - 99) vs 90 (ICR 85 -100) (p < 0.001) and median EQ-5D-3L utility' score 1 (ICR 1 - 1) vs 1 (ICR 1 - 1) (p = 0.021) Conclusions: We observed an improvement in quality of life based on the VAS score after undergoing an antiretroviral transition program, although pain worsened based on the utility score.
Keywords: Nevirapine, transition, dolutegravir. quality' of life